Key Drivers
- High gross margin
- Positive FCF
- Persistent losses
AIAI Summary
Mirum has evolved into a hybrid—a growing, high‑margin commercial cash generator from LIVMARLI and bile‑acid products that materially de‑risks pure R&D upside—yet the stock's valuation now hinges on multiple near‑term pivotal readouts (VISTAS/EXPAND/AZURE) that could sharply re‑rate the company, so investors should weigh the attractive cash runway and improving EBITDA against concentrated clinical-event risk and watch for stable distributor/order patterns or at least one positive pivotal result before adding size.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High gross margin
- •Positive FCF
- •Persistent losses
MIRM pairs very high gross margins, strong cash and free cash flow with ongoing operating/net losses and elevated leverage-relative valuation, making it liquid but profitability-challenged and likely overvalued.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Lower lows
- •Recent overshoot
MIRM is in a clear downtrend over the last month, sliding roughly 16% from about $105.16 to $88.51 with lower highs/lows and momentum biased toward further weakness.
Rough ~16% drop from $105.16 to $88.51 over last month indicating sustained selling pressure
Sentiment & News
Key News Insights:
- •Strong revenues
- •Enrollment complete
- •Insider selling
Mirum posted ~50% revenue growth and a narrower Q4 loss while completing enrollment in key Livmarli and brelovitug trials with top-line readouts expected H2/Q4 2026 amid positive analyst ratings and notable insider/institutional selling.
Commercial traction plus impending pivotal readouts support upside potential, but insider/institutional selling and execution risk could pressure sentiment
Similar Companies in Healthcare
Other companies in the same sector with AI ratings